IBX 2.50% 3.9¢ imagion biosystems limited

In March 2023 the Company received feedback from the FDA...

  1. 264 Posts.
    lightbulb Created with Sketch. 70
    In March 2023 the Company received feedback from the FDA pertaining to its clinical development plans and intent to proceed with a mul-site Phase 2 study in the U.S. The Phase 2 study will be used to opmize dose and imaging schedules as well as explore various endpoints for clinical validity.
 
watchlist Created with Sketch. Add IBX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.